Cipher Pharmaceuticals Inc. has appointed Ralph Bohrer as the president and general manager of its subsidiary located in the United States. Read More »

Altan Pharma Ltd. announced this week the signing of a licensure agreement that will commercialize a generic version of caspofungin. Read More »

The American Society of Health-System Pharmacists (ASHP) has published a guide called "The Pharmacist’s Guide to Antimicrobial Therapy and Stewardship" to assist health care providers in fighting antimicrobial resistance to guarantee that patients are given the best treatments. Read More »

Astellas Pharma Inc. this week announced personnel changes for the company. Read More »

Amgen announced earlier this week that it has submitted to the U.S. Food and Drug Administration (FDA) a supplemental Biologics License Application (sBLA) for BLINCYTO (blinatumomab) that will include new information to support the treatment of pediatric and adolescent patients who have been diagnosed with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Read More »

According to new data, researchers have found that stroke patients who have received medication via mail-service from pharmacies that offer the perk are more likely to follow their regimens and the guidelines of the medication. Read More »

BioPlus Specialty Pharmacy has released a new version of its HCV Treatment Path app. Read More »

Actinium Pharmaceuticals announced this week that its choice for Clinical Research Organization (CRO) that will conduct its Phase 3 Iomab-B clinical trial is Medpace. Read More »

The American Pharmacists Association (APhA), in its efforts to uphold high standards of practicing nuclear pharmacy, has announced a series of educational sessions that will focus on nuclear pharmacy at its 2016 APhA Annual Meeting and Exposition Read More »

The American Pharmacists Association (APhA) announced this week that it has unveiled a new resource center in its continuing fight against prescription drug and opioid abuse that will provide pharmacists with more information pertaining to opioid use, abuse and misuse. Read More »

Astellas Pharma Inc. announced earlier this week that is has obtained approval from the Ministry of Health, Labour and Welfare in Japan for a supplemental new drug application (sNDA) for its product Kiklin capsules 250mg. Read More »

Earlier this week, the National Association of Chain Drug Stores (NACDS) issued a letter to members of the U.S. Senate to try and convince them to pass a legislation that would push for health care and enforcement authorities to work together for a solution to the prescription drug abuse problem in order to uphold patients’ legitimate access to medicines. Read More »

Prime Therapeutics LLC, a company that manages pharmacy benefits and serves more than 26 million people, recently named Jonathan B. Gavras, M.D., as its new chief medical officer (CMO). Read More »

AstraZeneca has announced it has completed an agreement that will transfer the rights of Moventig (naloxegol) to Kyowa Hakko Kirin subsidiary, ProStrakan Group. Read More »

Endocare Inc. has announced it has signed an exclusive agreement with R-Action Distribution Sarl, which is a subsidiary of R-Action SAS, that will allow the distribution of its Endocare Cryoablation technology in France and Switzerland. Read More »

AstraZeneca announced this week that it has agreed to the terms of a licensing agreement with China Medical System Holdings Ltd. (CMS) that will give CMS commercialization rights for Plendil (felodipine) in China. Read More »

Generic Pharmaceutical Association (GPhA) CEO and President Chip Davis stated in a recent press release that generic drug savings were imperative to long-term solutions to rising health costs and explained that the focus should be on increasing pharmaceutical competition and expanding access to safe, effective and more affordable generic drugs. Read More »

Aldeyra Therapeutics Inc. has reported that its Phase 2a clinical trial of topical ocular NS2 has shown positive results. Read More »

GenSight Biologics S.A. announced this week that the first patient has enrolled in the company’s two parallel Phase 3 trials for GS010, a medicine designed to treat Leber’s Hereditary Optic Neuropathy (LHON). Read More »

Dan Durham, the EVP for Health Policy of the Biotechnology Innovation Organization (BIO), has released a statement in response to the White House’s announcement about its intent to fast-track the Precision Medicine Initiative. Read More »